NCT06244745 (LETRODON) is a Phase 3 clinical trial of Administration of letrozole in Luteinised Follicular Cyst, sponsored by IVI Madrid.

Who is sponsoring NCT06244745?

NCT06244745 is sponsored by IVI Madrid.

What drugs are being tested in NCT06244745?

Interventions in NCT06244745: Administration of letrozole.

What condition does NCT06244745 study?

NCT06244745 studies Luteinised Follicular Cyst.

Is NCT06244745 still recruiting?

NCT06244745 is currently recruiting now. Last updated 21 May 2025.

Last reviewed 2025-05-21 · How we verify

NCT06244745: LETRODON

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.

Recruiting now Phase 3 Last updated 21 May 2025

What this trial tests

Phase 3 trial testing Administration of letrozole in Luteinised Follicular Cyst in 152 participants. Currently enrolling.

Timeline

15 December 2023

Primary endpoint
1 May 2025

31 May 2025

Quick facts

Lead sponsor	IVI Madrid
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	152
Start date	15 December 2023
Primary completion	1 May 2025
Estimated completion	31 May 2025
Sites	1 location across Spain

Drugs / interventions tested

Administration of letrozole — full drug profile →

Conditions studied

Luteinised Follicular Cyst — all drugs for Luteinised Follicular Cyst →

Sponsor

IVI Madrid — full company profile →

Who can join

Adults 18 to 34, female only, with Luteinised Follicular Cyst. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this trial is to determine whether the use of letrozole during the luteal phase in oocyte donors diminishes the ovarian volume, as well as to evaluate its effect on the duration of the luteal phase, taking into account hormonal and biochemical markers. Two groups will be established with random allocation of patients and 1:1 proportionality, as follows: * Control group: No specific treatment. * Study group: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other IVI Madrid trials

Trials by the same sponsor.

NCT05606679 — Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. · unknown
NCT05508217 — Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development · unknown
NCT02718105 — Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate · completed
NCT04778358 — Higher Dose of Rekovelle in Oocyte Donors · Phase 2 · completed
NCT04058678 — Effects of Telomerase Reactivation With Danazol in Ovarian Function. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06244745 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IVI Madrid
Last refreshed: 21 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06244745.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing